001     169929
005     20240229133659.0
024 7 _ |a 10.1016/j.celrep.2021.109394
|2 doi
024 7 _ |a pmid:34289372
|2 pmid
024 7 _ |a 2211-1247
|2 ISSN
024 7 _ |a 2639-1856
|2 ISSN
024 7 _ |a altmetric:110155856
|2 altmetric
037 _ _ |a DKFZ-2021-01635
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Dieter, Sebastian
|0 P:(DE-He78)34c336827b750ba10a020fd62ec4664f
|b 0
|e First author
|u dkfz
245 _ _ |a Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.
260 _ _ |a [New York, NY]
|c 2021
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1627464317_3145
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B280#
520 _ _ |a Novel treatment options for metastatic colorectal cancer (CRC) are urgently needed to improve patient outcome. Here, we screen a library of non-characterized small molecules against a heterogeneous collection of patient-derived CRC spheroids. By prioritizing compounds with inhibitory activity in a subset of-but not all-spheroid cultures, NCT02 is identified as a candidate with minimal risk of non-specific toxicity. Mechanistically, we show that NCT02 acts as molecular glue that induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. Knockout of CCNK or CDK12 decreases proliferation of CRC cells in vitro and tumor growth in vivo. Interestingly, sensitivity to pharmacological CCNK/CDK12 degradation is associated with TP53 deficiency and consensus molecular subtype 4 in vitro and in patient-derived xenografts. We thus demonstrate the efficacy of targeted CCNK/CDK12 degradation for a CRC subset, highlighting the potential of drug-induced proteolysis for difficult-to-treat types of cancer.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a CCNK
|2 Other
650 _ 7 |a CDK12
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a molecular glue degrader
|2 Other
650 _ 7 |a targeted protein degradation
|2 Other
700 1 _ |a Siegl, Christine
|b 1
700 1 _ |a Codo, Paula Luciana
|0 P:(DE-He78)456affe157d8bee8a41108100e104e92
|b 2
700 1 _ |a Huerta, Mario
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Ostermann-Parucha, Anna Lena
|0 P:(DE-He78)a27ddea8f7f0a3bace5e6a586a32279a
|b 4
|u dkfz
700 1 _ |a Schulz, Erik
|b 5
700 1 _ |a Zowada, Martina K
|b 6
700 1 _ |a Martin, Sylvia
|0 P:(DE-He78)5ef9ea2b7d03595663ed98fd407bba69
|b 7
|u dkfz
700 1 _ |a Laaber, Karin
|0 P:(DE-He78)2edb00bc9fd4fe7c858c2838ce1c0024
|b 8
|u dkfz
700 1 _ |a Nowrouzi, Ali
|b 9
700 1 _ |a Blatter, Mona
|0 P:(DE-He78)e60f04da55f0193520fabc5e75a1de8c
|b 10
|u dkfz
700 1 _ |a Kreth, Sina
|0 P:(DE-He78)21d657d65d4ad0fd8b0bbfe10fa65172
|b 11
|u dkfz
700 1 _ |a Westermann, Frank
|0 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
|b 12
|u dkfz
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 13
|u dkfz
700 1 _ |a Uhrig, Ulrike
|b 14
700 1 _ |a Putzker, Kerstin
|b 15
700 1 _ |a Lewis, Joe
|b 16
700 1 _ |a Haegebarth, Andrea
|b 17
700 1 _ |a Mumberg, Dominik
|b 18
700 1 _ |a Holton, Simon J
|b 19
700 1 _ |a Weiske, Joerg
|b 20
700 1 _ |a Toepper, Lena-Marit
|b 21
700 1 _ |a Scheib, Ulrike
|b 22
700 1 _ |a Siemeister, Gerhard
|b 23
700 1 _ |a Ball, Claudia R
|0 P:(DE-He78)7a10ea1b9b2872da9f375002c44ddfce
|b 24
|u dkfz
700 1 _ |a Kuster, Bernhard
|b 25
700 1 _ |a Stoehr, Gabriele
|b 26
700 1 _ |a Hahne, Hannes
|b 27
700 1 _ |a Johannes, Sarah
|b 28
700 1 _ |a Lange, Martin
|b 29
700 1 _ |a Herbst, Friederike
|b 30
700 1 _ |a Glimm, Hanno
|0 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9
|b 31
|u dkfz
773 _ _ |a 10.1016/j.celrep.2021.109394
|g Vol. 36, no. 3, p. 109394 -
|0 PERI:(DE-600)2649101-1
|n 3
|p 109394
|t Cell reports
|v 36
|y 2021
|x 2211-1247
909 C O |o oai:inrepo02.dkfz.de:169929
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)34c336827b750ba10a020fd62ec4664f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)456affe157d8bee8a41108100e104e92
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a27ddea8f7f0a3bace5e6a586a32279a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)5ef9ea2b7d03595663ed98fd407bba69
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)2edb00bc9fd4fe7c858c2838ce1c0024
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)e60f04da55f0193520fabc5e75a1de8c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)21d657d65d4ad0fd8b0bbfe10fa65172
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)7a10ea1b9b2872da9f375002c44ddfce
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL REP : 2019
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-03
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-02-03
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)
|0 LIC:(DE-HGF)CCBYNCNDNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-03
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELL REP : 2019
|d 2021-02-03
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-03
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-03
920 1 _ |0 I:(DE-He78)B280-20160331
|k B280
|l B280 Translationale funktionelle Krebsgenomik
|x 0
920 1 _ |0 I:(DE-He78)B087-20160331
|k B087
|l B087 Neuroblastom Genomik
|x 1
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 2
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK DD zentral
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B280-20160331
980 _ _ |a I:(DE-He78)B087-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21